20. October 2026

Swiss Nuclear Forum establishes the Swiss Nuclear Medicine Section

Olten - Through the Swiss Nuclear Medicine Section, the Swiss Nuclear Forum brings together representatives from the fields of medicine, industry, research and professional associations. The goal is to improve nuclear medicine diagnosis and therapy, strengthen the supply of radionuclides and facilitate access to new procedures.

(CONNECT) The Swiss Nuclear Forum has established the Swiss Nuclear Medicine Section to improve the framework conditions for nuclear medicine diagnosis and therapy, strengthen the supply of radionuclides and facilitate access to new procedures. The section is organized as an association and brings together representatives from medicine, industry, research and professional associations. According to a statement, it replaces the former Swiss Alliance for Innovation in Nuclear Medicine “whose work it continues, and intends to establish itself as a long-term entity”. The founding meeting took place in Olten in the canton of Solothurn on 12 October.

Nuclear medicine enables the precise diagnosis and treatment of diseases such as cancer. The new section is now committed to ensuring a reliable supply of radionuclides and radiopharmaceuticals and aims to remove regulatory and political obstacles hindering the technology. Among other things, the section will draw on the white paper from the former Alliance, which identifies areas for action in research and development, regulation, financing, infrastructure and the supply chain.

Konrade von Bremen was elected president of the Section. As an internal medicine specialist, she served as CEO of SWAN Isotopen AG for many years and combines medical experience with extensive knowledge of the industrial side of nuclear medicine. Niklaus Schäfer, chief physician and full professor in the Department of Nuclear Medicine and Molecular Imaging at the University Hospital of Lausanne (CHUV), was elected vice president. Founding members and members of the executive board also include Novartis Pharma Switzerland from Basel, Molecular Partners from Schlieren, the Paul Scherrer Institute (PSI) based in Villigen, the Baden Cantonal Hospital (KSB) and the Gösgen Nuclear Power Plant. The section is also open to other companies, organizations and individuals. ce/nta

Categories
Energy & Automation Life sciences & health